Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Heart Failure Reports
Published in: Current Heart Failure Reports 3/2024

15-04-2024 | Heart Failure | Review

Putting More Weight on Obesity Trials in Heart Failure

Authors: Josephine Harrington, Naveed Sattar, G Michael Felker, James L. Januzzi, Carolyn S. P. Lam, Neha J. Pagidipati, Ambarish Pandey, Harriette G. C. Van Spall, Darren K. McGuire

Published in: Current Heart Failure Reports | Issue 3/2024

Login to get access

Abstract

Purpose of Review

To review ongoing and planned clinical trials of weight loss among individuals with or at high risk of heart failure.

Recent Findings

Intentional weight loss via semaglutide among persons with heart failure and preserved ejection fraction and obesity significantly improves weight loss and health status as assessed by the KCCQ-CSS score and is associated with improvements in 6-min walk test.

Summary

Ongoing and planned trials will explore the role of intentional weight loss with treatments such as semaglutide or tirzepatide for individuals with heart failure across the entire ejection fraction spectrum.
Literature
1.
The GBD 2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 Years. N Engl J Med. 2017;377:13–27.
2.
Sarma S, Sockalingam S, Dash S. Obesity as a multisystem disease: trends in obesity rates and obesity-related complications. Diabetes Obes Metab. 2021;23(Suppl 1):3–16.PubMedCrossRef
3.
Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity among adults and youth: United States, 2015–2016. NCHSData Brief. 2017;288:8.
4.
Sattar N, McMurray J, Borén J, Rawshani A, Omerovic E, Berg N, et al. Twenty years of cardiovascular complications and risk factors in patients with type 2 diabetes: a nationwide Swedish cohort study. Circulation. 2023;147:1872–86.PubMedCrossRef
5.
Rawshani A, Rawshani A, Franzén S, Sattar N, Eliasson B, Svensson A-M, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379:633–44.PubMedCrossRef
6.••
Kenchaiah S, Pocock SJ, Wang D, Finn PV, Zornoff LAM, Skali H, et al. Body mass index and prognosis in patients with chronic heart failure. Circulation. 2007;116:627–36. Landmark paper showing that each 1 point increase in BMI is associated with a 5% increase in risk of HF for men, and 7% increase in risk for women.PubMedCrossRef
7.
Ndumele CE, Matsushita K, Lazo M, Bello N, Blumenthal RS, Gerstenblith G, et al. Obesity and subtypes of incident cardiovascular disease. J Am Heart Assoc. 2016;5:e003921.PubMedPubMedCentralCrossRef
8.
Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation. 2017;136:6–19.PubMedPubMedCentralCrossRef
9.
Adamson C, Jhund PS, Docherty KF, Bělohlávek J, Chiang C-E, Diez M, et al. Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. Eur J Heart Fail. 2021;23:1662–72.PubMedCrossRef
10.
Adamson C, Kondo T, Jhund P, de Boer RA, Honorio JWC, Claggett B, et al. Dapagliflozin for heart failure according to body mass index: the DELIVER trial. Eur Heart J. 2022;43:4406–17.PubMedPubMedCentralCrossRef
11.
Alexander JK, Amad KH, Cole VW. Observations on some clinical features of extreme obesity, with particular reference to cardiorespiratory effects. Am J Med. 1962;32:512–24.CrossRef
12.
Kasper EK, Hruban RH, Baughman KL. Cardiomyopathy of obesity: a clinicopathologic evaluation of 43 obese patients with heart failure. Am J Cardiol. 1992;70:921–4.PubMedCrossRef
13.
Rabbia F, Silke B, Conterno A, Grosso T, De Vito B, Rabbone I, et al. Assessment of cardiac autonomic modulation during adolescent obesity. Obes Res. 2003;11:541–8.PubMedCrossRef
14.
Henning RJ. Obesity and obesity-induced inflammatory disease contribute to atherosclerosis: a review of the pathophysiology and treatment of obesity. Am J Cardiovasc Dis. 2021;11:504–29.PubMedPubMedCentral
15.
Alpert MA, Lavie CJ, Agrawal H, Aggarwal KB, Kumar SA. Obesity and heart failure: epidemiology, pathophysiology, clinical manifestations, and management. Transl Res. 2014;164:345–56.PubMedCrossRef
16.••
Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in Patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389:1069–84. STEP HFpEF is the first randomized clinical trial to show that intentional weight loss (via semaglutide) results in significant improvement in clinical status for patients with heart failure and preserved ejection fraction.PubMedCrossRef
17.
The LOOK AHEAD Investigators. Cardiovascular effectsof intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145–54.CrossRef
18.
19.
20.
21.
22.
Sharma A, Lavie CJ, Borer JS, Vallakati A, Goel S, Lopez-Jimenez F, et al. Meta-analysis of the relation of body mass index to all-cause and cardiovascular mortality and hospitalization in patients with chronic heart failure. Am J Cardiol. 2015;115:1428–34.PubMedCrossRef
23.
Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997;349:1050–3.PubMedCrossRef
24.
Sperrin M, Candlish J, Badrick E, Renehan A, Buchan I. Collider bias is only a partial explanation for the obesity paradox. Epidemiology. 2016;27:525–30.PubMedPubMedCentralCrossRef
25.
Butt JH, Petrie MC, Jhund PS, Sattar N, Desai AS, Køber L, et al. Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox. Eur Heart J. 2023;44:1136–53.PubMedPubMedCentralCrossRef
26.
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989–1002.PubMedCrossRef
27.
Butler J, Shahzeb Khan M, Lindenfeld J, Abraham WT, Savarese G, Salsali A, et al. Minimally clinically important difference in health status scores in patients with HFrEF vs HFpEF. JACC Heart Fail. 2022;10:651–61.PubMedCrossRef
28.
Borlaug BA, Kitzman DW, Davies MJ, Rasmussen S, Barros E, Butler J, et al. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial. Nat Med. 2023;29:2358–65.
29.
Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221–32.PubMedCrossRef
30.
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205–16.PubMedCrossRef
31.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–44.PubMedCrossRef
32.
Lingvay I, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity (Silver Spring). 2023;31:111–22.PubMedCrossRef
33.
34.
Khan MS, Fonarow GC, McGuire DK, Hernandez AF, Vaduganathan M, Rosenstock J, et al. Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure. Circulation. 2020;142:1205–18.PubMedCrossRef
35.
Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2016;316:500–8.PubMedPubMedCentralCrossRef
36.
Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hänselmann A, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017;19:69–77.PubMedCrossRef
37.
Rao VN, Fudim M, Mentz RJ, Michos ED, Felker GM. Regional adiposity and heart failure with preserved ejection fraction. Eur J Heart Fail. 2020;22:1540–50.PubMedCrossRef
38.
Sorimachi H, Obokata M, Takahashi N, Reddy YNV, Jain CC, Verbrugge FH, et al. Pathophysiologic importance of visceral adipose tissue in women with heart failure and preserved ejection fraction. Eur Heart J. 2020;42:1595–605.PubMedCentralCrossRef
39.
Xu C, Guo Y, Zhang S, Lai Y, Huang M, Zhan R, et al. Visceral adiposity index and the risk of heart failure, late-life cardiac structure, and function in ARIC study. Eur J Prev Cardiol. 2023;30:1182–92.PubMedCrossRef
40.•
Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res. 2022;18(18):3434–50. An excellent review of the mechanisms and pathophysiology underlying heart failure with preserved ejection fraction in patients with obesity.CrossRef
41.
Madamanchi C, Alhosaini H, Sumida A, Runge MS. Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure. Int J Cardiol. 2014;176:611–7.PubMedPubMedCentralCrossRef
42.
Hollstein T, Schlicht K, Krause L, Hagen S, Rohmann N, Schulte DM, et al. Effect of various weight loss interventions on serum NT-proBNP concentration in severe obese subjects without clinical manifest heart failure. Sci Rep. 2021;11:10096.PubMedPubMedCentralCrossRef
43.
Fedele D, Bicchiega V, Collo A, Barutta F, Pistone E, Gruden G, et al. Short term variation in NTproBNP after lifestyle intervention in severe obesity. PLoS ONE. 2017;12:e0181212.PubMedPubMedCentralCrossRef
44.
45.
46.
47.
Novo Nordisk A/S. The cardiovascular safety of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once-weekly in participants with obesity and established cardiovascular disease [Internet]. clinicaltrials.gov. Report No.: NCT05669755. 2023. https://​clinicaltrials.​gov/​ct2/​show/​NCT05669755.
48.
Rivus Pharmaceuticals, Inc. Exploratory Phase 2A, double-blind, placebo-controlled, dose escalation study to determine the safety, tolerability, PD, and PK of HU6 for the Treatment of subjects with obese heart failure with preserved ejection fraction (HFpEF) [Internet]. clinicaltrials.gov. Report No.: NCT05284617. 2023. https://​clinicaltrials.​gov/​study/​NCT05284617.
49.
Amgen. A Phase 2 randomized, placebo-controlled, double-blind, dose-ranging study to evaluate the efficacy, safety, and tolerability of AMG 133 in adult subjects with overweight or obesity, with or without type 2 diabetes mellitus [Internet]. clinicaltrials.gov. Report No.: NCT05669599. https://​clinicaltrials.​gov/​study/​NCT05669599. Accessed Aug 2023.
50.
Batsis JA, Sarr MG, Collazo-Clavell ML, Thomas RJ, Romero-Corral A, Somers VK, et al. Cardiovascular risk after bariatric surgery for obesity. Am J Cardiol. 2008;102:930–7.PubMedPubMedCentralCrossRef
51.
Doumouras AG, Wong JA, Paterson JM, Lee Y, Sivapathasundaram B, Tarride J-E, et al. Bariatric surgery and cardiovascular outcomes in patients with obesity and cardiovascular disease. Circulation. 2021;143:1468–80.PubMedCrossRef
52.
Fisher DP, Johnson E, Haneuse S, Arterburn D, Coleman KJ, O’Connor PJ, et al. Association between bariatric surgery and macrovascular disease outcomes in patients with type 2 diabetes and severe obesity. JAMA. 2018;320:1570–82.PubMedPubMedCentralCrossRef
53.
Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24:1553–64.PubMedPubMedCentralCrossRef
54.
St Clair Gibson A, Goedecke JH, Harley YX, Myers LJ, Lambert MI, Noakes TD, et al. Metabolic setpoint control mechanisms in different physiological systems at rest and during exercise. J Theor Biol. 2005;236:60–72.PubMedCrossRef
55.
Metadata
Title
Putting More Weight on Obesity Trials in Heart Failure
Authors
Josephine Harrington
Naveed Sattar
G Michael Felker
James L. Januzzi
Carolyn S. P. Lam
Neha J. Pagidipati
Ambarish Pandey
Harriette G. C. Van Spall
Darren K. McGuire
Publication date
15-04-2024
Publisher
Springer US
Published in
Current Heart Failure Reports / Issue 3/2024
Print ISSN: 1546-9530
Electronic ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-024-00655-z

Other articles of this Issue 3/2024

Current Heart Failure Reports 3/2024 Go to the issue

Review

Economic Considerations of Cardiovascular Implantable Electronic Devices for The Treatment of Heart Failure

Review

Catheter Ablation of Ventricular Tachycardia in Ischemic Heart Disease: What Is Known and New Perspectives

Review

(Non)-Exertional Variables of Cardiopulmonary Exercise Testing in Heart Failure with and Without Cardiac Amyloidosis

Review

Relevance of Cardiovascular Exercise in Cancer and Cancer Therapy-Related Cardiac Dysfunction

ReviewPaper

Chronic Obstructive Pulmonary Disease in Heart Failure: Challenges in Diagnosis and Treatment for HFpEF and HFrEF

Review

Non-Coding Ribonucleic Acids as Diagnostic and Therapeutic Targets in Cardiac Fibrosis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits